Finance

Lists
Why is ADPT up 3.58%?
Dive Deeper
ADPT:NASDAQ
Adaptive Biotechnologies Corp
$28.35
+3.58%
(+0.98) 1D
$28.35
0.00% (0.00)
After hours
Closed: Oct 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ADPT...
Open
$27.59
High
$28.41
Low
$27.31
Mkt. cap
4.52B
Avg. vol.
2.23M
Volume
1.58M
52-wk high
$29.96
52-wk low
$12.00
EPS
-$0.41
Beta
2.09
Shares outstanding
159.60M
No. of employees
624
Open
$27.59
High
$28.41
Low
$27.31
Mkt. cap
4.52B
Avg. vol.
2.23M
Volume
1.58M
52-wk high
$29.96
52-wk low
$12.00
EPS
-$0.41
Beta
2.09
Shares outstanding
159.60M
No. of employees
624
News stories
From web sources and news partners
About Adaptive Biotechnologies Corp
CEOChad Robins
Employees624
Founded2009
HeadquartersSeattle, Washington, United States
SectorHealth care
Websiteadaptivebiotech.com
Analyst ratings
Based on 9 analysts giving stock ratings to ADPT in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ADPT in the last 3 months.
Highest
Current $28.35
$35.00 (+23.46%)
Average
$29.36 (+3.56%)
Lowest
$22.00 (-22.40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Subbu Nambi
Guggenheim
Buy
Maintained
$32.00
+12.9%
10/01/2026
Evie Koslosky
Goldman Sachs
Buy
Initiated
$35.00
+23.5%
09/29/2026
Mark Massaro
BTIG
Buy
Reiterated
$34.00
+19.9%
09/22/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/17/2026
David Westenberg
Piper Sandler
Buy
Maintained
$27.50
-3%
08/24/2026
Sebastian Sandler
J.P. Morgan
Buy
Maintained
$27.00
-4.8%
07/30/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Maintained
$22.00
-22.4%
07/30/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/30/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$28.00
-1.2%
07/30/2026
Andrew Brackmann
William Blair
Buy
Reiterated
-
-
06/16/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.25 / -$0.13
-87.20%miss
Revenue / Est. (USD)
71.55M / 65.45M
+9.32%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
93.97M
71.68M
70.87M
71.55M
Cost of goods sold
41.83M
39.99M
42.33M
39.32M
Cost of revenue
41.83M
39.99M
42.33M
39.32M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41.43M
44.04M
47.33M
47.58M
Operating expense
41.86M
44.47M
47.75M
48.00M
Total operating expenses
83.68M
84.45M
90.08M
87.32M
Operating income
10.29M
-12.77M
-19.21M
-15.77M
Other non operating income
-
-
-
-
EBT including unusual items
9.54M
-13.58M
-20.02M
-39.94M
EBT excluding unusual items
9.54M
-13.87M
-20.15M
-16.21M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
9.55M
-13.58M
-20.03M
-39.79M
Net profit margin
10.16%
-18.94%
-28.27%
-55.61%
Earnings per share
0.06
-0.09
-0.13
-0.25
Interest and investment income
2.23M
1.86M
1.94M
2.26M
Interest expense
-2.97M
-2.95M
-2.89M
-2.69M
Net interest expenses
-745.00K
-1.09M
-945.00K
-438.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
14.70M
-8.58M
-15.37M
-12.08M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps